csirt@kutim:~/threat-intel/cve/CVE-2025-4575

Katalog CVE

CVSS 6.5 · Medium EPSS 0,36%

Kerentanan Improper Certificate Validation pada openssl. Skor CVSS 3.1 6.5 (Medium) menurut CISA ADP.

Deskripsi (NVD)

Issue summary: Use of -addreject option with the openssl x509 application adds a trusted use instead of a rejected use for a certificate. Impact summary: If a user intends to make a trusted certificate rejected for a particular use it will be instead marked as trusted for that use. A copy & paste error during minor refactoring of the code introduced this issue in the OpenSSL 3.5 version. If, for example, a trusted CA certificate should be trusted only for the purpose of authenticating TLS servers but not for CMS signature verification and the CMS signature verification is intended to be marked as rejected with the -addreject option, the resulting CA certificate will be trusted for CMS signature verification purpose instead. Only users which use the trusted certificate format who use the openssl x509 command line application to add rejected uses are affected by this issue. The issues affecting only the command line application are considered to be Low severity. The FIPS modules in 3.5, 3.4, 3.3, 3.2, 3.1 and 3.0 are not affected by this issue. OpenSSL 3.4, 3.3, 3.2, 3.1, 3.0, 1.1.1 and 1.0.2 are also not affected by this issue.

Rincian

Terbit di NVD
22 Mei 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
6.5 (Medium), sumber CISA ADP
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:N/I:L/A:L · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-295: Improper Certificate Validation
EPSS (30 hari)
0,36% peluang dieksploitasi; lebih tinggi dari 28,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
openssl openssl Versi 3.5.0

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.